Pruritis Clinical Trial
Official title:
Nalbuphine for the Treatment of Opioid Induced Pruritus in Children
Itching is a frequent and disturbing side effect of the use of pain medication such as
morphine. In the post-operative period, it can be more distressing to pediatric patients
than their pain. The current first line treatment, an antihistamine (Benadryl), has a low
efficacy. This treatment causes sleepiness and may be dangerous when used in combination
with other drugs.
Nalbuphine has analgesic properties similar to morphine as well as the ability to reverse
some morphine-induced side effects, such as respiratory depression and itching. Nalbuphine
has been used effectively for patients undergoing Caesarean sections. However, the
effectiveness of nalbuphine in the pediatric population has not been investigated.
We want to determine the efficacy of nalbuphine in the treatment of itching after morphine
for postoperative pain relief. We will use a novel method to measure the effect of the
treatment using an intensity scale before and after the drug, to determine the intensity
difference.
PURPOSE Primary To determine the efficacy of nalbuphine (50 - 100 mcg/kg intravenously) in
the treatment of opioid induced pruritus in a multi-center tertiary care pediatric patient
population.
Secondary Determine the effect of treatment with nalbuphine on a subjects analgesia and
level of sedation.
HYPOTHESIS
Primary Outcome:
Nalbuphine will be effective in the treatment of opioid induced pruritus; a 50% reduction in
pruritus intensity will be considered clinically significant.
Secondary Outcome:
Treatment with nalbuphine will not result in attenuation of analgesia or an increase in
sedation
JUSTIFICATION Itch is a frequent and disturbing side effect of opioid use. A recent internal
review of the pediatric pain service at the University of Alberta Hospital, Edmonton,
Alberta found a 40% incidence of pruritus in patients receiving opioids. A similar review at
British Columbia Children's Hospital demonstrated a 22% of patients incidence of pruritus.
OBJECTIVES The compare the efficacy of nalbuphine to placebo for the treatment of
opioid-induced pruritus. It is anticipated that nalbuphine will result in a greater than 50%
reduction in pruritus intensity.
RESEARCH METHOD This study will be a randomized, double-blinded, placebo controlled trial of
nalbuphine for the treatment of opioid-induced pruritus. Pruritus intensity will be measured
using a standardized assessment tool / Color Analog Scale (CAS). This is a metric scale
which will be used to quantify pruritus on a scale of zero to ten. Using this scale a score
of zero is represented by white, increasing pruritus severity being represented by darker
shades of the color red, along a ruler.
Data analysis will be based on intenton to treat. It will be a multi-center study involving
tertiary care centers with acute pediatric pain services.
Subjects will be divided into two groups by computer generated block randomization; one
group will receive treatment with nalbuphine while the other will receive placebo. The
patient and investigator will be blinded to the treatment administered.
REASON FOR PLACEBO CONTROLLED STUDY DESIGN Current first line therapy for opioid induced
pruritus, with diphenhydramine is associated with a low efficacy (33%) (1). Recognizing that
there can be up to 30% self report response to placebo, it is felt that conducting this
study as a placebo-controlled trial will be necessary for the demonstration of significant
improvement in pruritus intensity.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04518618 -
Effect of Intrathecal Naloxone in the Incidence of Pruritis After C.S
|
N/A | |
Completed |
NCT00693654 -
Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis Patients
|
Phase 4 | |
Completed |
NCT03816891 -
Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis
|
Phase 2 | |
Recruiting |
NCT05936567 -
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
|
Phase 2 | |
Completed |
NCT01114672 -
A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients
|
Phase 4 | |
Not yet recruiting |
NCT06226610 -
Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic
|
Phase 2 | |
Withdrawn |
NCT02909569 -
Relieving Chronic Itch: Oral Medication
|
Phase 2 |